Key Insights

Highlights

Treatment Research

1 treatments under study, led by Mirdametinib

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Research Network

Common Treatments

  • Mirdametinib1

Active Sponsors

  • National Cancer Institute Nci1

Related Conditions

  • Congenital Melanocytic Nevus1
  • Astrocytoma1
  • Pediatric Tumors1
  • Neurocutaneous Melanocytosis1
  • Large And Giant Congenital Melanocytic Nevi1

Activity Timeline